CVS Health
CVS
$98.11
+3.11%
CVS Health Corporation is a diversified healthcare giant operating in the Medical - Healthcare Plans industry, integrating retail pharmacy, pharmacy benefit management (PBM), and health insurance services under one roof. The company is a dominant market leader and a vertically integrated healthcare behemoth, distinct for its unique combination of over 9,000 retail stores, the Caremark PBM, and the Aetna health insurer. The current investor narrative is heavily focused on regulatory tailwinds and margin recovery, as evidenced by a recent stock surge following a favorable $13 billion Medicare payment decision from CMS, which has improved the profit outlook for its insurance segment and highlighted a perceived valuation gap with peers.…
CVS
CVS Health
$98.11
Related headlines
Investment Opinion: Should I buy CVS Today?
Rating & Thesis: CVS is a HOLD. The core thesis is that the recent regulatory-driven surge and low forward valuation are compelling, but they are fully offset by extreme earnings volatility and execution risk required to bridge the valuation gap. While analyst sentiment is strengthening (e.g., Bernstein's March 2026 upgrade), the stock needs to prove it can deliver stable profitability.
Supporting Evidence: The forward PE of 10.03x is the primary valuation attraction, implying significant earnings growth from the trailing EPS. Revenue growth remains robust at 8.17% YoY in Q4 2025, and free cash flow generation is strong at $7.81 billion TTM. However, the gross margin of 12.84% in Q4 is thin, and the debt-to-equity ratio of 1.24 indicates moderate leverage. The implied upside is tied entirely to achieving the analyst EPS average of $11.61; at that earnings level and a 10x multiple, the stock would be fairly valued near its current price, suggesting limited near-term upside without multiple expansion.
Risks & Conditions: The two biggest risks are 1) failure to stabilize quarterly earnings, and 2) compression of the forward PE multiple if growth disappoints. This Hold would upgrade to a Buy if the company demonstrates two consecutive quarters of stable, growing net income and the forward PE compresses further below 9x on sustained execution. It would downgrade to a Sell if revenue growth decelerates below 5% or if another substantial quarterly loss occurs. Relative to its own volatile history and the earnings recovery priced in, the stock is fairly valued, trading at the intersection of catalyst-driven optimism and fundamental uncertainty.
Sign up to view all
CVS 12-Month Price Forecast
CVS presents a classic 'show me' story. The valuation is compelling on a forward basis, and the recent regulatory catalyst is materially positive. However, the extreme quarterly earnings volatility and low profitability metrics create a high degree of uncertainty. The stock is likely to be range-bound until it strings together several quarters of stable execution, proving it can bridge the vast gap between its trailing and forward multiples. The stance would upgrade to bullish on evidence of sustained quarterly profit stability and downgrade to bearish on a recurrence of a major quarterly loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $127.54 and implied upside of +30.0% versus the current price.
Average Target
$127.54
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$78 - $128
Analyst target range
Analyst coverage for CVS is substantial, with 13 analysts providing estimates, indicating strong institutional interest. The consensus sentiment leans bullish, as evidenced by recent actions like Bernstein's upgrade to 'Outperform' in March 2026, though a specific consensus recommendation and average target price are not provided in the data. The estimated EPS range for the forward period is wide, from a low of $11.16 to a high of $12.32, with an average of $11.61. The high target likely assumes successful execution on Medicare Advantage growth and PBM margin stability, while the low target may factor in ongoing cost pressures and integration risks. The recent pattern of institutional ratings shows a mix of reiterations and one notable upgrade, suggesting a strengthening but still cautious analyst view as the company navigates post-catalyst execution.
Bulls vs Bears: CVS Investment Factors
The bull case for CVS is currently stronger, primarily driven by a powerful, recent regulatory catalyst and a compelling forward valuation. The bear case is grounded in legitimate concerns about extreme earnings volatility and the high expectations embedded in the current price. The single most important tension in the investment debate is whether the company can deliver the massive earnings recovery (implied by the forward PE of 10x) necessary to justify its current valuation, or if operational missteps will expose the stock's vulnerability given its elevated trailing multiple. The resolution of this earnings normalization will determine the direction of the stock over the next 12 months.
Bullish
- Regulatory Tailwind Boosts Outlook: The recent $13 billion Medicare Advantage payment increase from CMS directly improves the profit outlook for CVS's Aetna insurance segment. This catalyst has driven a 13.24% stock surge in one month, highlighting a significant positive re-rating based on improved revenue visibility.
- Strong Forward Valuation at 10x PE: The forward PE ratio of 10.03x is exceptionally low, pricing in a significant earnings recovery from the trailing PE of 56.87x. This valuation gap suggests substantial upside if the company delivers on the forecasted average EPS of $11.61, implying the market is not yet assigning a premium for the integrated model.
- Robust Revenue Growth and Scale: Q4 2025 revenue of $105.69 billion grew 8.17% year-over-year, demonstrating the company's massive scale and growth trajectory despite earnings volatility. The Pharmacy segment ($61.62B) and Premiums ($34.02B) provide diversified, recurring revenue streams.
- Healthy Free Cash Flow Generation: Trailing twelve-month free cash flow of $7.81 billion provides strong internal funding capability for dividends, debt reduction, and strategic investments. This financial flexibility is a key strength for a capital-intensive, vertically integrated healthcare company.
Bearish
- Extreme Quarterly Earnings Volatility: Profitability is highly inconsistent, with a Q4 2025 net income of $2.94 billion followed by a substantial Q3 net loss of -$3.98 billion. This volatility, with a net margin of just 0.44%, raises serious questions about the sustainability and predictability of earnings.
- Elevated Trailing PE Signals High Expectations: The trailing PE of 56.87x is elevated and sits above recent historical averages, indicating the market is already pricing in a significant earnings recovery. This leaves little margin for error; any disappointment in the expected earnings normalization could trigger multiple compression.
- Weak Short-Term Liquidity Position: A current ratio of 0.84 indicates the company has less current assets than current liabilities, suggesting a tight short-term liquidity position. This could constrain operational flexibility and increase reliance on external financing or cash flow timing.
- Modest Profitability Metrics: Return on Equity of 2.35% and Return on Assets of 2.47% reflect modest profitability relative to shareholder and asset capital. For a company of its scale and integration, these low returns suggest operational inefficiencies or intense competitive pressures on margins.
CVS Technical Analysis
The stock is in a sustained recovery trend, having gained 18.20% over the past year. With a current price of $82.09, it is trading at approximately 92% of its 52-week range ($58.35 to $85.15), positioning it near recent highs which reflects strong momentum but also raises questions about potential overextension. The 1-month price change of +13.24% significantly outpaces the 3-month gain of +10.16%, indicating that recent momentum is accelerating sharply, likely driven by the positive Medicare news in early April. This short-term surge diverges from the stock's more moderate longer-term trajectory, signaling a powerful, catalyst-driven move rather than a gradual trend. Key technical support is anchored at the 52-week low of $58.35, while immediate resistance sits at the 52-week high of $85.15; a decisive breakout above $85.15 would signal a continuation of the bullish momentum. The stock's beta of 0.505 indicates it is roughly 50% less volatile than the broader market (SPY), which is notable given the recent price surge and suggests the stock has defensive characteristics that may limit downside risk during market corrections.
Beta
0.59
0.59x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$58-$98
Price range past year
Annual Return
+62.2%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | +25.6% | +8.2% |
| 3m | +25.9% | +9.0% |
| 6m | +26.1% | +10.5% |
| 1y | +62.2% | +26.5% |
| ytd | +22.4% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue growth is robust but volatile on a quarterly basis; Q4 2025 revenue was $105.69 billion, representing a strong 8.17% year-over-year increase, though this follows a significant net loss in Q3. The Pharmacy Revenue segment, at $61.62 billion for the period, is the primary growth driver, supplemented by Premiums of $34.02 billion. Profitability is inconsistent, with Q4 2025 net income of $2.94 billion and a gross margin of 12.84%, but this solid quarter was preceded by a substantial Q3 net loss of -$3.98 billion, indicating significant quarterly earnings volatility. The trailing twelve-month free cash flow is a healthy $7.81 billion, providing strong internal funding capability. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.24 and a current ratio of 0.84, which indicates adequate but not robust short-term liquidity, while the return on equity of 2.35% reflects modest profitability relative to shareholder capital.
Quarterly Revenue
$105.7B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.12%
Latest Quarter
Free Cash Flow
$7.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given the company's positive net income in the most recent quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 56.87x, while the forward PE is substantially lower at 10.03x; this wide gap implies the market expects a significant earnings recovery and normalization in the coming year, pricing in the positive impact of recent regulatory developments. Compared to sector averages (data not available in the provided set), a direct peer comparison cannot be quantified, but the low forward PE suggests the market may not be assigning a premium for the company's integrated model if earnings deliver. Historically, the stock's own PE ratio has fluctuated wildly, from as low as -6.02x in Q3 2025 to 227.49x in Q3 2024; the current trailing PE of 56.87x sits above its recent historical average, suggesting the market is pricing in improved and more stable future earnings, leaving little margin for disappointment.
PE
56.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -9x~227x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CVS faces significant financial risk from extreme quarterly earnings volatility, as evidenced by the swing from a Q3 2025 net loss of -$3.98 billion to a Q4 profit of $2.94 billion. This inconsistency makes forecasting difficult and increases stock price sensitivity to individual quarterly reports. Furthermore, a current ratio of 0.84 indicates weak short-term liquidity, which could pressure the company during periods of tight cash flow or unexpected expenses. The modest profitability metrics, with a net margin of 0.44% and ROE of 2.35%, suggest the integrated model has yet to deliver superior returns on capital, posing a fundamental risk to shareholder value creation.
Market & Competitive Risks: The primary market risk is valuation compression. The stock trades at a trailing PE of 56.87x, which is elevated historically and prices in a near-perfect earnings recovery. If execution falters, the multiple could contract sharply toward the forward PE of 10x, representing significant downside. Competitive risks are omnipresent in the low-margin pharmacy and PBM businesses, and regulatory scrutiny remains a constant threat despite the recent Medicare win. The stock's low beta of 0.505 offers some defensive protection but does not immunize it from sector-specific headwinds like drug pricing reforms or insurer margin pressure.
Worst-Case Scenario: The worst-case scenario involves a failure to realize the projected earnings recovery, compounded by a resurgence of cost pressures in the PBM or insurance segments. This could trigger a wave of analyst downgrades and a re-rating from a growth-adjusted multiple back to a value multiple. The realistic downside is anchored by the 52-week low of $58.35, which represents a potential loss of approximately -29% from the current price of $82.09. A re-test of this level is plausible if the company reports another significant quarterly loss or guides earnings materially below the $11.61 EPS consensus, eroding confidence in the forward narrative.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company's inability to produce consistent quarterly profits, as seen in the swing from a $2.94B profit to a -$3.98B loss within two quarters. 2) Execution & Integration Risk: Failure to realize synergies from its vertical integration (Aetna, Oak Street Health) or to manage margins in its competitive PBM and retail segments. 3) Valuation Compression Risk: If the promised earnings recovery falters, the elevated trailing PE of 56.87x could contract violently. 4) Regulatory Risk: Despite the recent Medicare win, the healthcare sector remains perpetually exposed to changes in government reimbursement and drug pricing policies.
The 12-month forecast is bifurcated, with a base case target range of $80-$90 (50% probability), a bull case of $92-$102 (30% probability), and a bear case of $58-$70 (20% probability). The base case, which is most likely, assumes CVS meets the analyst consensus EPS of ~$11.61 and trades at a stable forward PE of 9-11x. The forecast hinges almost entirely on the company's ability to stabilize its quarterly earnings. The recent positive Medicare catalyst supports the bull case, but the stock's history of volatility underpins the bear case, which aligns with a re-test of its 52-week low of $58.35.
CVS is a tale of two valuations: it appears significantly overvalued on a trailing basis (PE of 56.87x) but deeply undervalued on a forward basis (PE of 10.03x). This dichotomy means the market is pricing in a massive earnings recovery. Compared to its own volatile history, the current trailing multiple is elevated, suggesting high expectations. The forward multiple of 10x is low for a diversified healthcare leader, implying the market is skeptical or assigning no premium. Therefore, the stock is fairly valued only if the expected earnings normalization occurs perfectly; it is overvalued if earnings disappoint and undervalued if they exceed expectations.
CVS is a conditional buy, suitable for investors with a moderate risk tolerance and a 12-18 month horizon. The forward PE of 10.03x offers compelling value if the company delivers its forecasted EPS of $11.61, implying significant earnings growth. However, it is not a good buy for those seeking stability, as extreme quarterly earnings volatility (e.g., Q3 2025's -$3.98B loss) presents substantial risk. The recent 13.24% monthly surge on Medicare news may have captured near-term upside, making entry timing crucial. It is a good buy for value investors who believe in the earnings recovery narrative and can withstand potential short-term turbulence.
CVS is more suitable for a medium- to long-term investment horizon (minimum 2-3 years) rather than short-term trading. The investment thesis revolves around the multi-quarter process of earnings normalization and integration synergy realization, which cannot be judged in a single quarter. Its low beta of 0.505 indicates lower short-term volatility relative to the market, but its own fundamental volatility makes it a poor short-term trading vehicle. The 3.38% dividend yield provides some income for long-term holders. Therefore, investors should be prepared to hold through potential quarterly earnings disappointments to allow the long-term value proposition to unfold.